These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32302790)

  • 1. Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.
    Reddy D; Shah TT; Dudderidge T; McCracken S; Arya M; Dobbs C; Emberton M; Fiorentino F; Day E; Prevost AT; Staffurth J; Sydes M; Winkler M; Ahmed HU
    Contemp Clin Trials; 2020 Jun; 93():105999. PubMed ID: 32302790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study.
    Day E; Prevost AT; Sydes MR; Reddy D; Shah TT; Winkler M; Dudderidge T; Staffurth J; McCracken S; Khoo V; Jadav P; Klimowska-Nassar N; Sasikaran T; Ahmed HU; Fiorentino F
    Trials; 2021 Aug; 22(1):547. PubMed ID: 34407860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Local Treatments After Focal Therapy for Prostate Cancer.
    Marra G; Valerio M; Emberton M; Heidenreich A; Crook JM; Bossi A; Pisters LL
    Eur Urol Oncol; 2019 Sep; 2(5):526-538. PubMed ID: 31412013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.
    Stranne J; Brasso K; Brennhovd B; Johansson E; Jäderling F; Kouri M; Lilleby W; Meidahl Petersen P; Mirtti T; Pettersson A; Rannikko A; Thellenberg C; Akre O
    Scand J Urol; 2018; 52(5-6):313-320. PubMed ID: 30585526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
    Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
    Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
    Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
    BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    McPartlin AJ; Glicksman R; Pintilie M; Tsuji D; Mok G; Bayley A; Chung P; Bristow RG; Gospodarowicz MK; Catton CN; Milosevic M; Warde PR
    Cancer; 2016 Aug; 122(16):2595-603. PubMed ID: 27219522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control.
    van Son MJ; Peters M; Reddy D; Shah TT; Hosking-Jervis F; Robinson S; Lagendijk JJW; Mangar S; Dudderidge T; McCracken S; Hindley RG; Emara A; Nigam R; Persad R; Virdi J; Lewi H; Moore C; Orczyk C; Emberton M; Arya M; Ahmed HU; van der Voort van Zyp JRN; Winkler M; Falconer A
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1120-1128. PubMed ID: 33934114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol.
    Mathier E; Althaus A; Zwahlen D; Lustenberger J; Zamboglou C; De Bari B; Aebersold DM; Guckenberger M; Zilli T; Shelan M
    BMJ Open; 2024 Jan; 14(1):e075846. PubMed ID: 38296279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
    BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
    Ward JF; Moul JW
    Curr Opin Urol; 2005 May; 15(3):187-95. PubMed ID: 15815196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)
    Yokomizo A; Wakabayashi M; Satoh T; Hashine K; Inoue T; Fujimoto K; Egawa S; Habuchi T; Kawashima K; Ishizuka O; Shinohara N; Sugimoto M; Yoshino Y; Nihei K; Fukuda H; Tobisu KI; Kakehi Y; Naito S;
    Eur Urol; 2020 Jun; 77(6):689-698. PubMed ID: 31866092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.